Correct Answer: B. Propranolol
Propranolol is a non-selective beta-blocker that is contraindicated in pregnancy due to its association with intrauterine growth restriction (IUGR), neonatal hypoglycemia, and bradycardia. Non-selective beta-blockers cross the placenta readily and block both β1 and β2 receptors in the fetus, impairing placental blood flow and fetal metabolic adaptation. The Indian guidelines (ICMR/FOGSI) and Harrison's Textbook recommend avoiding non-selective beta-blockers in pregnancy. While labetalol (combined α and β-blocker) and methyldopa are safe first-line agents, and hydralazine is used for hypertensive emergencies in pregnancy, propranolol's fetal toxicity profile makes it unsuitable. The key discriminator is that propranolol causes placental insufficiency and fetal compromise, whereas the other three agents have established safety records in Indian obstetric practice and are listed in standard antepartum hypertension protocols.
Why the other options are wrong
A. Alpha methyldopa — Methyldopa is the gold standard first-line antihypertensive in pregnancy across all trimesters, including in Indian guidelines. It has the longest safety record (>40 years) with no teratogenic or fetotoxic effects. It crosses the placenta minimally and does not impair placental perfusion. This is a trap for students who confuse it with other antihypertensives; methyldopa is explicitly recommended by FOGSI and WHO for chronic hypertension in pregnancy. C. Labetalol — Labetalol is a combined α1 and non-selective β-blocker that is safe in pregnancy because its α-blocking effect prevents the fetal bradycardia and IUGR seen with pure beta-blockers. It is now preferred over methyldopa in many Indian centers for second and third trimester hypertension. The NBE trap here is confusing labetalol (safe) with pure beta-blockers like propranolol (unsafe)—the selective α-blocking component is the safety feature. D. Hydralazine — Hydralazine is a vasodilator used for acute hypertensive crises in pregnancy (e.g., preeclampsia) and is safe for both mother and fetus. It does not cross the placenta significantly and maintains placental perfusion. Indian obstetric protocols include IV hydralazine as a first-line agent for hypertensive emergencies. The trap is assuming all antihypertensives are equally safe; hydralazine's vasodilatory mechanism makes it ideal for pregnancy.
High-Yield Facts
- Propranolol in pregnancy → IUGR, neonatal hypoglycemia, bradycardia (non-selective β-blockade crosses placenta)
- Methyldopa is the gold standard first-line agent for chronic hypertension in pregnancy (all trimesters)
- Labetalol is safe in pregnancy because α-blockade prevents fetal bradycardia (unlike pure β-blockers)
- Hydralazine is the agent of choice for hypertensive emergencies in pregnancy (IV route)
- Non-selective beta-blockers (propranolol, atenolol) are avoided; selective β1-blockers (labetalol, nebivolol) are preferred
- ACE inhibitors and ARBs are absolutely contraindicated in pregnancy (teratogenic, especially 2nd/3rd trimester)
Mnemonics
SAFE in Pregnancy Hypertension Methyldopa (first-line, all trimesters) | Labetalol (second/third trimester) | Hydralazine (acute crisis) | Nifedipine (calcium channel blocker, also safe) AVOID in Pregnancy ACE-I/ARBs (teratogenic) | Non-selective Beta-blockers (propranolol, atenolol → IUGR) | Diuretics (reduce placental perfusion) | NSAIDs (3rd trimester risk)
NBE Trap
NBE pairs "antihypertensives in pregnancy" with methyldopa and labetalol to lure students into thinking all beta-blockers are safe. The trap is confusing labetalol (safe, combined α/β-blocker) with pure non-selective beta-blockers like propranolol (unsafe due to IUGR and fetal bradycardia).
Clinical Pearl
In Indian obstetric practice, propranolol is explicitly avoided because it causes placental insufficiency leading to IUGR—a major cause of perinatal morbidity in resource-limited settings. Methyldopa remains the safest choice for chronic hypertension across all trimesters, while labetalol is increasingly preferred for acute control in the second and third trimester due to its superior hemodynamic profile.
_Reference: KD Tripathi Pharmacology Ch. 31 (Antihypertensives); Harrison's Principles of Internal Medicine Ch. 290 (Hypertension in Pregnancy); FOGSI Clinical Practice Guidelines on Hypertension in Pregnancy_